Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Pemigatinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre
    Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre

    19 Apr 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/innovent-announces-overall-survival-results-of-phase-2-study-of-pemazyre-pemigatinib-in-chinese-patients-with-advanced-cholangiocarcinoma-presented-at-aacr-annual-meeting-2023-301798880.html

    PR NEWSWIRE
    19 Apr 2023
    Share Share
    Incyte Announces Japanese Approval of Pemazyre for the Treatment of MLNs
    Incyte Announces Japanese Approval of Pemazyre for the Treatment of MLNs

    27 Mar 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230326005073/en

    BUSINESSWIRE
    27 Mar 2023
    Share Share
    New treatment for rare cancer cholangiocarcinoma approved in Australia
    New treatment for rare cancer cholangiocarcinoma approved in Australia

    15 Sep 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/new-treatment-for-rare-cancer-cholangiocarcinoma-approved-in-australia-301625157.html

    PRNEWSWIRE
    15 Sep 2022
    Share Share
    FDA approves Incyte’s Pemazyre for treating myeloid/lymphoid neoplasms
    FDA approves Incyte’s Pemazyre for treating myeloid/lymphoid neoplasms

    29 Aug 2022

    // PHARMACEUTICAL-TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/fda-approves-incyte-pemazyre/

    PHARMACEUTICAL-TECHNOLOGY
    29 Aug 2022
    Share Share
    Innovent Nabs Approval of Pemazyre by NMPA for Cholangiocarcinoma
    Innovent Nabs Approval of Pemazyre by NMPA for Cholangiocarcinoma

    06 Apr 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/innovent-announces-the-approval-of-pemazyre-pemigatinib-by-the-nmpa-for-the-treatment-of-adults-with-locally-advanced-or-metastatic-cholangiocarcinoma-with-a-fgfr2-fusion-or-rearrangement-as-confirmed-by-a-validated-diagnostic--301518629.html

    PRNEWSWIRE
    06 Apr 2022
    Share Share
    Non-Muscle Invasive Bladder Cancer Pipeline Insights | Clinical Trials Report 2022 by DelveInsight
    Non-Muscle Invasive Bladder Cancer Pipeline Insights | Clinical Trials Report 2022 by DelveInsight

    31 Jan 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/01/31/2376027/0/en/Non-Muscle-Invasive-Bladder-Cancer-Pipeline-Insights-Clinical-Trials-Report-2022-by-DelveInsight.html

    GLOBENEWSWIRE
    31 Jan 2022
    Share Share